Int’l Biotechnology consults investors after fund manager resigns
In an unusual development, SV Health, fund manager of the £300m International Biotechnology Trust serves 12-month notice, saying it wants to focus on its healthcare venture business.
Investment company news brought to you by Citywire Financial Publishers Limited and Quoted Data by Marten & Co.
In an unusual development, SV Health, fund manager of the £300m International Biotechnology Trust serves 12-month notice, saying it wants to focus on its healthcare venture business.
SV Health, manager of the £300m International Biotechnology Trust, serves 12-month notice, saying it wants to focus on its healthcare venture business.
Share issue of £1.3bn Brevan Howard hedge fund was mainly backed by institutional and professional investors, but private investors subscribed for £66m of sterling shares.
Brevan Howard hedge fund lifts assets by a quarter after institutional and professional investors take advantage of keenly-priced share issue from the all-weather performer.
Analysts' concerns over the price of this week's fund raise have not deterred investors, although the company has perhaps had to settle for less than it wanted.
(Update) Concerns over price of this week’s fundraise have not deterred investors, although the company has perhaps had to settle for less than it wanted. It may bode well for the flotation of rival infrastructure fund AT85.
Life sciences fund has plenty of cash to pursue its ambition to become a £5bn biotech platform, even if investors are giving its shares the cold shoulder at the moment.
Former manager of top-performing AEW UK Reit joins LXI Reit Advisors as chief investment officer as its long-leased property fund reports good rent rises but sees its shares falter on a corporate connection to embattled Home Reit.
The private equity fund of funds applies a management fee cap as it looks to attract investors and re-rate shares that trail 37% below the value of the trust’s assets.
The European private equity investment trust buys its first cyber insurance platform Baobab and adds to fast-growing digital bank, Zopa.
Shares in Jupiter’s under-pressure growth capital fund drop 6% on deal to buy £20m of unquoted Starling bank from Jupiter UK Mid Cap fund, run by co-manager Richard Watts. Analysts say the transaction increases Chrysalis' risks.
Fund group sells stake in unlisted digital bank Starling and rules its open-ended funds will no longer invest in private companies. Jupiter's closed-end fund Chrysalis is one of the buyers though.
Developed by Moore-Wilson